Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Ofatumumab
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Pathological mechanisms in progressive multiple sclerosis.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Thrombotic microangiopathy associated with interferon beta.
Differential roles of microglia and monocytes in the inflamed central nervous system.
European Medicines Agency
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Biogen Reports Another Tecfidera PML Case
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Generic interferon-beta
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
National Cancer Institute Search for Clinical Trials
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Pages